Global Filgrastim biosimilar market is expected to grow at rapid pace with strong presence of major players such as Aryogen Biopharma, Cadila Pharmaceutical, Claris Life Sciences, Dr Reddy’s Laboratories, Intas Biopharmaceuticals, Adello Biologics, Hosp

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on ' Global Filgrastim Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2027'

Request for ToC/Proposal: https://bit.ly/2UNpfGA

Filgrastim is G-CSF that stimulates bone marrow to produce more neutrophils. The drug was developed by Amgen and marketed under the trade name of Neupogen. It was approved in the U.S. by Food Drug and Administration in February 1991. Neupogen is approved for various indications such as febrile neutropenia. It is indicated to reduce the recovery time of neutrophil and the duration of fever following chemotherapy treatment of patients suffering with acute myeloid leukemia. The patient who are undergoing myeloablative chemotherapy in nonmyeloid malignancies, filgrastim reduces the duration of neutropenia and neutropenia-related clinical sequelae. In addition, it is used as stem cell mobilizer and for the treatment of cyclic‚ genital‚ or idiopathic neutropenia.
The patents on Neupogen expired in the US in December 2013 and in Europe in 2006. Entry of filgrastim biosimilar into market such as Zarzio (Sandoz), Nufil (Biocon), Grastofil (Apotex) and many more have boosted the growth of the filgrastim biosimilar market.

The Filgrastim biosimilar market is fragmented/consolidated with presence of many/few players that operates in local as well as international market.
Global Filgrastim biosimilar Market reports cover prominent players like Aryogen Biopharma, Cadila Pharmaceutical, Claris Life Sciences, Dr Reddy’s Laboratories, Intas Biopharmaceuticals, Adello Biologics, Hospira(Pfizer), Gennova Biopharmaceuticals (Emcure), Teva Pharmaceutical Industries, Sandoz and many more..

Curious about this latest version of report?

Obtain Report Details @ https://bit.ly/2UNpfGA

Market Segments
• Global Filgrastim biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Application
o Febrile Neutropenia
o Genital Neutropenia
o Idiopathic Neutropenia and others

• Global Filgrastim Biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Distribution Channel
o Hospital Pharmacy
o Online Pharmacy
o Retail Pharmacy
o Other Direct Distribution Channels

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global Filgrastim biosimilar market
 To receive industry overview and future trends Filgrastim biosimilar market
 To analyze the Filgrastim biosimilar market drivers and challenges
 To get information on Filgrastim biosimilar market size and forecast
 To get details on Filgrastim biosimilar clinical trial/pipeline analysis
 Originator drug historic revenue
 Originator drug key news/industry activities
 Major Mergers & Acquisition in Filgrastim biosimilar industry

For More Information @ https://bit.ly/2UNpfGA

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Email us: info@insightaceanalytic.com
Call us: +1 718 593 4405
Pune, Maharashtra 411004

This release was published on openPR.